http://www.*.com.au/companies/news/5175/healthli...

http://www.proactiveinvestors.com.au/companies/news/5175/healthlinx-ltd-launches-ovarian-cancer-ovplex-test-into-uk-market-5175.html

HealthLinx Ltd launches ovarian cancer OvPlex test into UK market

HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex on 25 February 2010.

The company obtained European Certification for OvPlex paving the way to market and sell the product within the European community.

Nick Gatsios, managing director of HealthLinx said the UK launch will be the first large scale roll out of OvPlex and HealthLinx will receive a royalty of approximately $70 per test.

The UK marketing launch of OvPlex on such a large scale will build a platform for HealthLinx to target other countries.

The company has opened discussions in Korea, China, other European countries for OvPlex and has been approached by some Central South American countries, providing strong commercial upside opportunities.

The recent announcement that OvPlex was awarded BioSpectrum Product of the Year in Asia Pacific for 2010 by an independent jury chaired by Dr G Steven Burrill of Burrill and Co, further supports the commercial opportunity for the product.

Each year 240,000 new cases of ovarian cancer are diagnosed worldwide and over 130,000 women die from the disease. The UK region accounts for over 7,000 of these diagnoses and 4,000 lives lost per year.